Methoden vergelijken
Bekijk de geselecteerde methoden naast elkaar; rijen die verschillen zijn gemarkeerd.
| Doelwitgemedieerde Geneesmiddeldispositie× | PopulatiPharmacodynamische Modellering× | |
|---|---|---|
| Vakgebied | Farmacologie | Farmacologie |
| Familie | Process / pipeline | Process / pipeline |
| Jaar van ontstaan≠ | 2001 | 1992 |
| Grondlegger≠ | Donald Mager and William Jusko | Lewis Sheiner and Stephen Roush |
| Type≠ | nonlinear PK modeling | dose-response modeling |
| Oorspronkelijke bron≠ | Mager, D. E., & Jusko, W. J. (2001). General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. Journal of Pharmacokinetics and Pharmacodynamics, 28(6), 507-532. DOI ↗ | Dahlström, B., & Nyberg, L. (1993). Population pharmacokinetics and pharmacodynamics. Clinical Pharmacokinetics, 24(1), 45-57. link ↗ |
| Aliassen≠ | TMDD, target-driven clearance | PopPD, population PD, hierarchical PD modeling |
| Verwant | 3 | 3 |
| Samenvatting≠ | Target-mediated drug disposition (TMDD) is a mechanistic framework describing nonlinear pharmacokinetics arising from drug binding to a target receptor or protein. Developed by Mager and Jusko in 2001, TMDD explains saturable clearance, dose-dependent half-lives, and time-dependent changes in plasma concentrations observed with protein therapeutics and some small-molecule drugs. | Population pharmacodynamic (PopPD) modeling integrates pharmacokinetics with individual dose-response relationships across patient populations to characterize drug efficacy and tolerability. Pioneered by Lewis Sheiner and colleagues, PopPD accounts for inter-individual variability in drug effects and enables rational dose optimization and response prediction. |
| ScholarGateGegevensset ↗ |
|
|